RxDoctor Payments Data

Gil Vardi, MD

Interventional Cardiology · Saint Louis, MONPI 1437173119

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (51.0%), other and education — rather than concentrated in one kind of arrangement. 49 manufacturers reported payments, led by Coala Life Inc at 45.5% of the total. Reporting peaked in 2020 at $38,454 and has fallen 84.3% since, to $6,026 in 2025. Among interventional cardiology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$105,725in general payments, 2019–2025

Across 508 payments — averaging $208.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coala Life Inc$48K
  • Angiodynamics, Inc.$43K
  • Biotronik Inc.$2K
  • Boston Scientific$2K
  • Novartis$2K
  • Medtronic$1K
  • plus $7K from 43 others
$1,895,152in research payments, 2019–2025

Across 119 payments — averaging $15,926 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cvrx, Inc.$1.3M
  • American Regent$433K
  • Novartis$83K
  • Cleerly, Inc.$41K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$37K
  • Boehringer Ingelheim International GmbH$30K

What the payments were for

  • Consulting fees$53,90051%
  • Travel & lodging$4,8575%
  • Food & beverage$9,9069%
  • Education$16,81116%
  • Other$20,25019%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$105,725 in reported general payments places this provider in the 90th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$308,860
Medicare patients
487
Services billed
4,203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban175$190,344
JardianceEmpagliflozin138$177,346
EntrestoSacubitril/Valsartan122$175,007
XareltoRivaroxaban126$133,246
Praluent PenAlirocumab94$90,847
FarxigaDapagliflozin Propanediol72$58,606
Repatha SureclickEvolocumab37$25,979
OzempicSemaglutide15$24,168
CorlanorIvabradine Hcl11$17,717
VeltassaPatiromer Calcium Sorbitex15$15,986
BrilintaTicagrelor12$13,871
MyrbetriqMirabegron13$6,348
Ranolazine ErRanolazine44$6,268
Atorvastatin Calcium309$3,558
ClopidogrelClopidogrel Bisulfate370$3,520

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$228$190,344175 claims
Boehringer IngelheimJardiance$223$177,346138 claims
NovartisEntresto$1,715$175,007122 claims
Johnson & JohnsonXarelto$285$133,246126 claims
AstraZenecaFarxiga, Brilinta$295$72,47784 claims
Novo NordiskOzempic$206$24,16815 claims
AmgenCorlanor$256$17,71711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 182 interventional cardiology providers in Missouri.

Other interventional cardiology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →